Herbas VPB

Print
EN | LT
LT - Vėžio gydymo būdas, panaudojant imuninės kontrolės taško inhibitorių; antikūnas, kuris suriša užprogramuotos mirties-1 receptorių (PD-1) arba užprogramuotos mirties ligandą 1 (PD-L1)
EN - METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)

Legal status

Patent in force

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. C07K 16/28 (2006.01)
A61K 39/395 (2006.01)
A61P 35/00 (2006.01)
A61K 39/00 (2006.01)
C12Q 1/6886 (2018.01)
C12Q 1/70 (2006.01)
G01N 33/574 (2006.01)
European patent
(11) Number of the document 3858859
(13) Kind of document T
(96) European patent application number 20214749.2
Date of filing the European patent application 2016-07-14
(97) Date of publication of the European application 2021-08-04
(45) Date of publication and mention of the grant of the patent 2025-10-29
(46) Date of publication of the claims translation 2026-01-26
Priority applications
(30) Number Date Country code
201562192396 P 2015-07-14 US
Inventors
(72)
MANEKAS, Demetrios , US
GROSSO, Joseph , US
ANDERSON, Jeffrey , US
Grantee
(73) Bristol-Myers Squibb Company , Route 206 and Province Line Road, Princeton, NJ 08543, US
Attorney or representative
(74) Jurga PETNIŪNAITĖ, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Title
(54) Vėžio gydymo būdas, panaudojant imuninės kontrolės taško inhibitorių; antikūnas, kuris suriša užprogramuotos mirties-1 receptorių (PD-1) arba užprogramuotos mirties ligandą 1 (PD-L1)
  METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)